05-15 ARGENX : Deutsche Bank reaffirms its Buy rating ZD
05-12 Argenx SE Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 10:40 AM
05-12 ARGENX : Bernstein reiterates its Buy rating ZD
05-11 ARGENX : Goldman Sachs keeps its Buy rating ZD
05-11 ARGENX : Gets a Buy rating from Barclays ZD
05-11 Argenx Wins FDA Approval Expanding Vyvgart Use to All Serotypes of Generalized Myasthenia Gravis MT
05-11 US FDA Approves Expansion of Indication for Argenx's Vyvgart MT
05-08 FDA Approves Label Expansion For Argenx Treatment of Autoimmune Disease DJ
05-08 Argenx announces U.S. FDA approval expanding Vyvgart and Vyvgart Hytrulo for use in all adult patients living with gMG RE
05-08 Argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG GL
05-08 Argenx SE Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG CI
05-08 ARGENX : Deutsche Bank remains its Buy rating ZD
05-08 ARGENX : Jefferies remains its Buy rating ZD
05-08 ARGENX : Buy rating from Goldman Sachs ZD
05-08 ARGENX : UBS remains Neutral ZD
05-08 ARGENX : DZ Bank remains its Buy rating ZD
05-08 ARGENX : Buy rating from Barclays ZD
05-07 Argenx SE, Q1 2026 Earnings Call, May 07, 2026
05-07 ARGENX : Bernstein keeps its Buy rating ZD
05-07 ARGENX : Barclays maintains a Buy rating ZD
05-07 Argenx Q1 Profit, Total Operating Income Increase MT
05-07 Argenx SE Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
05-07 Argenx Q1 total operating income USD 1.313 bln RE
05-07 Argenx Logs Improved Q1 Profit, Product Net Sales MT
05-07 Argenx Reports First Quarter 2026 Financial Results and Provides Business Update GL
No results for this search